SCIENCE
Multi-target Portfolio

SCIENCE

Multi-target Portfolio

Multi-target Portfolio

While our current focus is on bi-specific therapies, we are also actively exploring the development of next-generation multi-specific therapeutics—such as tri-specific and tetra-specific—to achieve more comprehensive modulation of the tumor microenvironment and further improve therapeutic outcomes.

T-sphaera Immuno-oncology Therapy (TSIT)

·
 Immuno-oncology Therapy
·
 Multi Immune Checkpoint Inhibitors
·
 Maximized Efficacy by the Engaging Effect of Cancer Cells and Immune Cells

T-sphaera Multi-target Therapy (TSMT)

·
 Multi-target Anticancer Treatment
·
 Incorporates Diverse Strategies – Primarily Targeting Tumor-specific Antigens and Modulating Immune Responses

We are actively engaged in the research and development of a diverse range of multi-target therapeutic candidates leveraging our proprietary T-sphaera platform. We are developing novel bi-specific therapeutic candidates that combine PD-1 or PD-L1 with an additional target, such as TIGIT, LAG-3, or VEGF, etc. These multi-specific candidates are designed to enhance anti-tumor efficacy by simultaneously modulating multiple immune or tumor-associated pathways, thereby overcoming immune resistance and promoting a more robust and durable anti-tumor response.
Mechanism of TSIT
(Checkpoint Inhibitor Immunotherapy)
 Images for illustrative purposes only. · Multi-target immunotherapies aim to overcome resistance seen with PD-1/PD-L1 monotherapies by synergistically enhancing T cell activation and anti-tumor immunity. · The combinations block multiple immune checkpoints simultaneously, leading to more sustained responses in tumors with complex immunosuppressive microenvironments.
Mechanism of TSMT
(VEGF x PD(L)1)
 Images for illustrative purposes only. · Combining PD-(L)1 and VEGF blockade can produce a synergistic anti-tumor effect by simultaneously enhancing immune cell infiltration and suppressing tumor angiogenesis. · Due to the broader distribution throughout the TME of VEGF, T-sphaera’s spherical structure can remain widely dispersed after binding to VEGF, which helps to enhance the antitumor activity, as compared to monotherapy or combination therapy.